Acupoint Stimulation Improves Postoperative Wound Pain
Launched by CHENG-HSIN GENERAL HOSPITAL · May 11, 2025
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Surgical wound length ≥ 10 cm
- • American Society of Anesthesiologists (ASA) physical status classification I to III
- • Receiving intravenous patient-controlled analgesia (IV PCA)
- • Clear consciousness and ability to communicate
- • Willingness to participate and provide informed consent
- Exclusion Criteria:
- • Presence of arrhythmia
- • Implanted artificial cardiac pacemaker
- • Cutaneous lesions at the acupoint or auricular application sites
- • History of chronic pain or abdominal surgery within the past 6 months
- • Non-ambulatory status prior to surgery
About Cheng Hsin General Hospital
Cheng-Hsin General Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and a robust framework for conducting research, the hospital fosters collaboration among multidisciplinary teams to explore new therapeutic options and enhance clinical practices. By leveraging state-of-the-art facilities and a patient-centered approach, Cheng-Hsin General Hospital aims to contribute significantly to the medical community and drive forward the development of effective treatments across various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, Peitou Dist, Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported